A new style of defibrillator can detect abnormal heart rhythms and
... complication-free for up to 180 days after the implantation and the S-ICD® was 100% effective at spotting and counteracting ventricular fibrillation, a uncoordinated contraction of the heart muscle which could lead on to a heart attack. A comparison between the ICDs and the S-ICD® is in motion. The ...
... complication-free for up to 180 days after the implantation and the S-ICD® was 100% effective at spotting and counteracting ventricular fibrillation, a uncoordinated contraction of the heart muscle which could lead on to a heart attack. A comparison between the ICDs and the S-ICD® is in motion. The ...
First use of cardiac contractility modulation (CCM) in a patient failing
... In a previous clinical study, it was shown that the acute haemodynamic effects of CRT and CCM signals are additive, when administered to patients with prolonged QRS duration and mechanical dyssynchrony [10]. This is because the mechanisms of these two types of therapy are different and unrelated [1] ...
... In a previous clinical study, it was shown that the acute haemodynamic effects of CRT and CCM signals are additive, when administered to patients with prolonged QRS duration and mechanical dyssynchrony [10]. This is because the mechanisms of these two types of therapy are different and unrelated [1] ...
Cardiac contractility modulation
Cardiac contractility modulation (CCM) is a treatment for patients with moderate to severe left ventricular systolic heart failure (NYHA class II–IV). The short- and long-term use of this therapy enhances both the strength of ventricular contraction and the heart’s pumping capacity. The CCM mechanism is based on stimulation of the cardiac muscle by non-excitatory electrical signals (NES). CCM treatment is delivered by a pacemaker-like device that applies the NES, adjusted to and synchronized with the electrical action in the cardiac cycle.In CCM therapy, electrical stimulation is applied to the cardiac muscle during the absolute refractory period. In this phase of the cardiac cycle, electrical signals cannot trigger new cardiac muscle contractions, hence this type of stimulation is known as a non-excitatory stimulation. However, the electrical CCM signals increase the influx of calcium ions into the cardiac muscle cells (cardiomyocytes). In contrast to other electrical stimulation treatments for heart failure, such as pacemaker therapy or implantable cardioverter defibrillators (ICD), CCM does not affect the cardiac rhythm directly. Rather, the aim is to enhance the heart’s natural contraction (the native cardiac contractility) sustainably over long periods of time. Furthermore, unlike most interventions that increase cardiac contractility, CCM is not associated with an unfavorable increase in oxygen demand by the heart (measured in terms of Myocardial Oxygen Consumption or MVO2). This may be explained by the beneficial effect CCM has in improving cardiac efficiency. A meta-analysis in 2014 and an overview of device-based treatment options in heart failure in 2013 concluded that CCM treatment is safe, that it is generally beneficial to patients and that CCM treatment increases the exercise tolerance (ET) and quality of life (QoL) of patients. Furthermore, preliminary long-term survival data shows that CCM is associated with lower long-term mortality in heart failure patients when compared with expected rates among similar patients not treated with CCM.